In recent years, genetic screening has become a critical tool for BC assessment, diagnosis and in guiding treatment choices [3, 4].Mutation profiling for BC has been an integral part of clinical care since the discovery of the BRCA1 and BRCA2 genes [5–7].Cases with BRCA1 and BRCA2 pathogenic mutations have a significantly increased risk of developing BC before the age of 50 years [8–11]. This evidence concerns the gene BRCA1 and breast cancer.